Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and efficacy of bi-weekly WH002(Paclitaxel Medium and Long Chain Fat Emulsion Injection,Cholesterol Bound) vs Paclitaxel both followed by bi-weekly Epirubicin and Cyclophosphamide as neoadjuvant treatment in women with HER2-negative breast cancer.
Phase:
PHASE1
Details
Lead Sponsor:
Beijing Wehand-Bio Pharmaceutical Co., Ltd
Collaborator:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences